Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SLMT vs BDRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDRX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–5 Matrix Metrics)

BDRX Overall Winner 6-Pillar Tally: SLMT 2 – 2 BDRX (2 Tie) Matrix Metrics: SLMT 5 – 2 BDRX

As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SLMT (SLMT) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). SLMT carries a Unified Composite Score of 43.0/100 (HOLD) at $2.24 (N/M Forward P/E, -4271.3% operating margin), whereas BDRX carries 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SLMT currently prints a higher short-term Unified Composite Score (43.0/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4271.3% operating margin) and revenue trajectory (-64.1% vs. +929.8% YoY).
  • Technical & Structure Timing Caution: SLMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile BDRX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLMT vs BDRX
SLMT US Equity
SLMT
Institutional Equity
$2.24
-13.85% 1D
Market Cap $28.6M
TTM Revenue $7.3M
Forward P/E N/M
Beta / 30D Vol 7.98β · 107% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $3.03 · SMA50: $3.35
BDRX NASDAQ Head-to-Head Winner
Biodexa Pharmaceuticals plc American Depositary Shs
Pharmaceutical Preparations
$1.88
-6.02% 1D
Market Cap $1.0M
TTM Revenue $83,000
Forward P/E N/M
Beta / 30D Vol 5.62β · 2621% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $2.73 · SMA50: $1.46

6-Pillar Scorecard Institutional Category Breakdown (SLMT 2 – 2 BDRX)

Columns: Metric · SLMT · BDRX
1. Valuation Multiples SLMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x 12.6x
2. Growth & Scale SLMT
Revenue Growth (YoY) +929.8% -64.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.3M $83,000
Market Cap $28.6M $1.0M
3. Profitability & Quality BDRX
Gross Margin 100.0% N/A
Operating Margin -4271.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -795.8% -42.0%
4. Balance Sheet & Cash Flow BDRX
Cash Generation (TTM) -$310M EBITDA -$8.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.73 Book/Sh · -795.8% ROE $138.06 Book/Sh · -42.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Infrastructure Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLMT (5) vs BDRX (2)
Institutional Metric SLMT BDRX Criterion Row Edge
Market Capitalization
Scale
$28.6M $1.0M Larger Scale SLMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+929.8% -64.1% Higher Growth SLMT
Operating Margin (TTM)
Profitability
-4271.3% 0.0% Higher Margin BDRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-795.8% -42.0% Higher ROE BDRX
52-Week Range Position
Momentum
26% ($1–$7) 18% ($0–$9) Stronger Trend SLMT
Beta / 30D Volatility
Risk Regime
7.98β · 107% Vol 5.62β · 2621% Vol Lower Realized Risk SLMT
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite SLMT
Trailing 12M Revenue (USD)
Operating Scale
$7.3M $83,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 12.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$310M EBITDA ($10.73 Book/Sh · -795.8% ROE) -$8.8M EBITDA ($138.06 Book/Sh · -42.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDRX +382.68 pp
SLMT: -29.78% · BDRX: +352.9%
3M Horizon BDRX +102.4 pp
SLMT: -46.15% · BDRX: +56.25%
6M Horizon BDRX +19.89 pp
SLMT: -62.73% · BDRX: -42.84%
1Y Horizon BDRX +9.89 pp
SLMT: -61.31% · BDRX: -51.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLMT vs BDRX. Trailing 12-month operating profitability (SLMT -4271.3% vs BDRX 0.0%) and valuation multiples (SLMT N/M vs BDRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SLMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.3M
Gross Margin100.0%
Op. Margin-4271.3%
ROE / Fwd P/E-795.8% · N/M
BDRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLMT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BDRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLMT Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $28.6M market capitalization and -4271.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BDRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLMT vs BDRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SLMT (SLMT) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). SLMT carries a Unified Composite Score of 43.0/100 (HOLD) at $2.24 (N/M Forward P/E, -4271.3% operating margin), whereas BDRX carries 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SLMT currently prints a higher short-term Unified Composite Score (43.0/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4271.3% operating margin) and revenue trajectory (-64.1% vs. +929.8% YoY). Technical & Structure Timing Caution: SLMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile BDRX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SLMT leads the Growth & Scale pillar: SLMT posts +929.8% YoY revenue growth and +0.0% YoY earnings growth on $7.3M TTM revenue (100.0% gross margin, -4271.3% operating margin), compared with BDRX at -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SLMT generates $7.3M in USD-normalized revenue versus $83,000 for BDRX. In operating R&D and SG&A reinvestment, SLMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BDRX.

SLMT screens cheaper on headline valuation multiples. SLMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLMT (-795.8% ROE) versus BDRX (-42.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SLMT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.98β · 107% Vol realized risk). By comparison, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.62β · 2621% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.